DAFTAR RUJUKAN

1. LeRoy EC, Silver RM. Systemic sclerosis and related syndrome: Epidemiology, Pathology
and Pathogenesis. In: Schumacher HR, Klippel JH, Koopman WJ (eds). Primer on the
Rheumatic Diseases. 10th ed. Arthritis Foundation, Atlanta, Georgia 1993: 118 – 20.

2. Steen VD, Medsger TA. Epidemiologi and Natural History of Systemic Sclerosis. Rheum Dis
Clin N Am 1990: 16 (1): 1 – 10.

3. Seibold JR. Systemic Sclerosis: Clinical Features. In: Klippel JH, Dieppe P (eds).
Rheumatology. 1st ed. Mosby-Year Book Europe Limited, London 1994: 8. 1-14.

4. Silman AJ, Newmwn J. Genetic and Environmental Factors in Scleroderma. Curr Op

Rheumatol 1994; 6(6): 607-11.

5. Smith EA, LeRoy EC. Systemic Sclerosis: Etiology and Pathogenesis. In: Klippel JH, Dieppe
P (eds). Rheumatology. 1st ed. Mosby-Year Book Europe Limited, London 1994: 9. 1-10.

6. Silver RM, Miller KS. Lung involvement in Systemic Sclerosis. Rheuma Dis Clin N Am
1990; 16 (1): 199-216.

7. Medsger TA, Steen V. Systemic Sclerosis and Related Syndromes: Clinical Features and
Treatment. In: Schumacher HR, Klippel JH, Koopman WJ (eds). Primer on the Rheumatic
Diseases. 10th ed. The Arthritis Foundation. Atlanta, Georgia 1993: 127-30.

8. Sjorgen RW. Gastrointestinal Motility Disorders in Scleroderma. Arthritis Rheuma 1994; 37

(9): 1265-82.

9. Postlethwaite AE. Early Immune Events in Scleroderma. Rheum Dis Clin N Am 1990; 16 (1):
125-40.

10. Reimer G. Autoantibodies Against Nuclear, Nucleolar and Mitochondrial Antigens in

Systemic Sclerosis. Rheuma Dis Clin N Am 1990; 16 (1): 169-84.

11. McHugh NJ, Whyte J, Harvey G et al. Anti-topoisomerase I antibodies in Siliaca-associated

Systemic Sclerosis: A Model for autoimmunity. Arthritis Rheum 1994; 37 (8): 1198-1205.
12. Hietarinta M. Ilonen J, Lassila O et al. Association of HLA antigen with anti-Sel-70
antibodies and alinical manifestations of Systemic Sclerosis. Br J Rheumatol 1994; 33: 323-6.

13. Weiner ES, Hildebrandt S, Senecal JL et al. Prognostic significance of anticentromere

antibodies and anti-topoasomerase I antibodies in Raynaud disease: A prospective study.
Arthritis Rheum 1991; 34 (1): 68-77.

14. Sato S, Ihn H, Kikuchi K et al. Antihistone antibodies in Systemic Sclerosis: Association with
Pulmonary Fibrosis. Arthritis Rheum 1994; 37 (3): 391-4.

15. White B. Immunologic aspect of Scleroderma. Curr Op Rheumatol 1994; 6 (6): 612-5.

16. Wigley FM. Clinical aspects of systemic and localized scleroderma. Curr Op Rheumatol
1994; 6 (6): 628-36.

17. Fiocco U, Rosada M, Cozzi L et al. Early phenotypic activation of circulating helper memory
T cells in scleroderma: correlation with disease activity. Ann Rheum Dis 1993; 52: 272-7.

18. Postletwite AE. Connective tissue metabolism including cytokines in scleroderma. Curr Op
Rheumatol 1994; 6 (6): 616-20.

19. Briggs D, Black C, Welsh K. Genetic factors in Scleroderma. Rheum Dis Clin N Am 1990;
16 (1): 31-52.

20. Genth E, Mierau R, Genetzky P et al. Immunogenetic associations of Scleroderma- related

antinuclear antibodies. Arthritis Rheum 1990; 33 (5): 657-65.

21. Kuwana M, Okano Y, Kaburaki J. Racial differences in the distribution of Systemic Sclerosis-
related serum anti-nuclear antibodies. Arthritis Rheum 1994; 37 (6): 902-6.

22. Carpentier PH, Maricq HR. Microvasculature in Systemic Sclerosis. Rheum Dis Clin N Am
1990; 16 (1): 75-92.

23. Kahaleh MB. Raynaud’s phenomenon and vascular disease in Scleroderma. Curr Op
Rheumatol 1994; 6 (6): 621-7.
24. Kahaleh MB. Matucci-Cerinic M. Raynaud’s phenomenon and Scleroderma: Dysregulated
Neuroendothelial Control of Vascular tone. Arthritis Rheum 1995; 18 (1): 1-4.

25. Clements PJ, Lachenbruch PA, Furst DE et al. Cardiac score: A semiquantitative measure of
cardiac invollement that improves prediction of prognosis in Systemic Sclerosis. Arthritis
Rheum 1991; 34 (11): 1371-80.

26. Clements PJ, Lachenbruch PA, Furst DE et al. Abnormalities of renal physiology in systemic
sclerosis: A prospective study with 10-year follow up. Arthritis Rheum 1994; 37 (1): 67-74.

27. Albar Z. Sklerosis sistemik. In: Soeparman (ed). Ilmu Penyakit Dalam. Jilid I. Edisi kedua.
Balai Penerbit FKUI, Jakarta: 1987: 747-52.

28. Steen VD. Systemic Sclerosis: Management. In: Klippel JH, Dieppe PA (eds). Rheumatology.
1st ed. Mosby-Year Book Europe Limited, London 1994: 10.1-8.

29. Duboc D, kahan A, Maziere B et al. The effect of nifedipine on myocardial perfusion and
metabolism in Systemic Sclerosis: A positron emission tomographic study. Arthritis Rheum
1991; 34 (2): 198-203.

30. Hoogen FHJ, Putte LBA. Treatment of Systemic sclerosis. Curr Op Rheumatol 1994; 6 (6):
637-41.

31. Torres MA, Furst DE Treatment of Generalized Systemic Sclerosis. Rheum Dis Clin N Am
1990; 16 (1): 217-42.

32. Steen VD, Lanz JK, Conte C et al. Therapy for severe interstitial lung disease in Systemic
Sclerosis: A retrospective study. Arthritis Rheum 1994; 37 (9): 1290-6.

33. Akesson A. Scheja A, Lundin A et al. Improved pulmonary function in systemic sclerosis
after treatment with cyclophosphamide. Arthritis Rheum 1994; 37 (50): 729-35.

34. Altman RD, Medsger TA, Bloch DA et al. Predictors of survival in Systemic sclerosis
(Scleroderma). Arthritis Rheum 1991; 34 (4): 403-13.